上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Savolitinib (Synonyms: 赛沃替尼; Volitinib; HMPL-504; AZD-6094) 纯度: 99.56%
Savolitinib (AZD-6094) 是一种高效选择性、口服生物利用度 c-Met 抑制剂,对 c-Met 和 p-Met 的 IC50 分别为 5 nM 和 3 nM。Savolitinib (AZD-6094) 以 ATP 竞争的方式选择性结合并抑制 c-Met 的激活,破坏 c-Met 信号转导途径。具有抗肿瘤活性。
Savolitinib Chemical Structure
CAS No. : 1313725-88-0
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥1899 | In-stock | |
2 mg | ¥1000 | In-stock | |
5 mg | ¥1600 | In-stock | |
10 mg | ¥2600 | In-stock | |
50 mg | ¥9000 | In-stock | |
100 mg | 询价 |
* Please select Quantity before adding items.
Savolitinib 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- Bioactive Compound Library Plus
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Drug Repurposing Compound Library
- Anti-COVID-19 Compound Library
- NMPA-Approved Drug Library
- Orally Active Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Anti-Lung Cancer Compound Library
- Angiogenesis Related Compound Library
- Targeted Diversity Library
- Anti-Liver Cancer Compound Library
- Anti-Colorectal Cancer Compound Library
生物活性 |
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity[1][2]. |
IC50 & Target |
IC50: 5 nM (c-Met) and 3 nM (p-Met)[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体内研究 (In Vivo) |
Savolitinib (Compound 28; 1-10.0 mg/kg; oral administration; daily; for 21 days; athymic nude mice) demonstrates dose-dependent tumor growth inhibition in a U87MG subcutaneous xenograft model. In addition, none of the mice in the dosing groups exhibits body weight loss during the experiment[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
345.36 |
||||||||||||||||
Formula |
C17H15N9 |
||||||||||||||||
CAS 号 |
1313725-88-0 |
||||||||||||||||
中文名称 |
赛沃替尼;沃利替尼 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 25 mg/mL (72.39 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务